Westwood Holdings Group Inc. increased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 0.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,033,484 shares of the medical instruments supplier’s stock after buying an additional 7,609 shares during the quarter. Becton Dickinson and accounts for approximately 1.7% of Westwood Holdings Group Inc.’s holdings, making the stock its 6th biggest position. Westwood Holdings Group Inc. owned approximately 0.39% of Becton Dickinson and worth $221,227,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of BDX. Legacy Advisors LLC lifted its position in shares of Becton Dickinson and by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after buying an additional 490 shares during the last quarter. Amica Retiree Medical Trust lifted its position in shares of Becton Dickinson and by 325.0% during the 4th quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 390 shares during the last quarter. Almanack Investment Partners LLC. acquired a new position in shares of Becton Dickinson and during the 4th quarter worth about $109,000. FTB Advisors Inc. lifted its position in shares of Becton Dickinson and by 114.2% during the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares during the last quarter. Finally, Advisors Preferred LLC acquired a new position in shares of Becton Dickinson and during the 4th quarter worth about $126,000. Institutional investors and hedge funds own 83.40% of the company’s stock.
Shares of NYSE BDX traded down $4.63 during mid-day trading on Friday, hitting $215.50. The company had a trading volume of 1,320,605 shares, compared to its average volume of 1,153,007. Becton Dickinson and Co has a one year low of $175.66 and a one year high of $248.39. The stock has a market capitalization of $58,607.96, a price-to-earnings ratio of 22.73, a PEG ratio of 1.60 and a beta of 1.15. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93.
Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the business posted $2.33 EPS. Becton Dickinson and’s revenue was up 5.4% on a year-over-year basis. sell-side analysts expect that Becton Dickinson and Co will post 10.95 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Friday, March 9th were given a dividend of $0.75 per share. The ex-dividend date of this dividend was Thursday, March 8th. This represents a $3.00 annualized dividend and a yield of 1.39%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 31.65%.
In other news, Director Timothy M. Ring sold 269,661 shares of Becton Dickinson and stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the sale, the director now directly owns 295,753 shares in the company, valued at $64,420,918.46. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Timothy M. Ring sold 176 shares of Becton Dickinson and stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $218.27, for a total transaction of $38,415.52. Following the completion of the sale, the director now owns 170,688 shares of the company’s stock, valued at $37,256,069.76. The disclosure for this sale can be found here. Insiders have sold 281,108 shares of company stock valued at $61,321,396 over the last 90 days. Company insiders own 1.00% of the company’s stock.
BDX has been the subject of several research analyst reports. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Morgan Stanley upped their price objective on Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 7th. KeyCorp initiated coverage on Becton Dickinson and in a research note on Friday, January 5th. They issued an “overweight” rating and a $260.00 price objective on the stock. Bank of America restated a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a research report on Friday, January 19th. Finally, Citigroup upgraded Becton Dickinson and from a “sell” rating to a “neutral” rating in a research report on Friday, January 5th. Six equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $240.53.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/becton-dickinson-and-co-bdx-is-westwood-holdings-group-inc-s-6th-largest-position.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.